Dynavax (DVAX) AI Stock Analysis

• Market Cap: $1.21B
• Dividend Yield: N/A
• Average Volume (3M): 1.46M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.36
• Revenue Growth: 26.73%
• EPS Growth: -310.39%
• Country: US
• Employees: 405
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 0.21
• Shares Outstanding: 117,267,480
• 10 Day Avg. Volume: 1,788,067
• 30 Day Avg. Volume: 1,464,418
• PEG Ratio: -0.12
• Price to Book (P/B): 2.78
• Price to Sales (P/S): 5.99
• P/FCF Ratio: 27.60
• Enterprise Value/Market Cap: 0.83
• Enterprise Value/Revenue: 3.02
• Enterprise Value/Gross Profit: 5.13
• Enterprise Value/Ebitda: -27.03
• 1Y Price Target: $21.00
• Price Target Upside: 93.91% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 5
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 58 Neutral
• Price Target: $10.50 ▼(-3.05% Downside)

Dynavax's overall stock score reflects a mixed financial performance with profitability challenges, offset by positive technical indicators and a strong earnings call. The strategic initiatives and revenue growth are promising, but valuation concerns and profitability issues weigh on the score.

Positive Factors

Revenue Growth

The consistent revenue growth from HEPLISAV-B indicates strong market demand and solidifies Dynavax's position in the hepatitis B vaccine market.

Strategic Partnerships

The partnership with Vaxart for an oral COVID-19 vaccine could diversify Dynavax's product offerings and enhance its competitive position in the vaccine market.

Pipeline Progress

Advancements in the shingles vaccine program demonstrate Dynavax's commitment to expanding its product pipeline, potentially leading to new revenue streams.

Negative Factors

Profitability Challenges

Persistent profitability issues could hinder Dynavax's ability to reinvest in growth and limit its financial flexibility over the long term.

Cash Position Decrease

The decrease in cash reserves, partly due to share repurchases, may constrain Dynavax's ability to fund future growth initiatives and operations.

Seasonality Impact

Seasonal demand fluctuations could impact revenue consistency, affecting financial performance predictability and planning.

Dynavax Business Overview & Revenue Model

Company Description

Dynavax Technologies Corporation is a biopharmaceutical company focused on developing and commercializing innovative vaccines and immunotherapies. The company is primarily engaged in the research and development of its proprietary toll-like receptor (TLR) platform, which is aimed at enhancing the immune response to infections and diseases. Dynavax's core product is HEPLISAV-B, a hepatitis B vaccine that has received regulatory approvals in various markets, including the United States. The company operates in the biotechnology sector and is dedicated to addressing unmet medical needs through its advanced therapeutic solutions.

How the Company Makes Money

Dynavax generates revenue primarily through the sales of its products, particularly HEPLISAV-B, which has been established as a key revenue stream following its approval and commercialization. The company also engages in collaborations and partnerships with other pharmaceutical companies, which may involve upfront payments, milestone payments, and royalties on future sales of products developed through these collaborations. These strategic partnerships help to bolster Dynavax's financial performance and can provide additional funding for its research and development activities.

Dynavax Financial Statement Overview

Summary

Dynavax's financial performance is mixed. Revenue growth and strong gross profit margins are positive, but negative net income and EBIT margins indicate profitability challenges. The balance sheet shows improved leverage but negative returns on equity. Cash flow generation is improving, but profitability issues remain a concern.

Income Statement

Dynavax's income statement shows mixed results. The company has experienced revenue growth in the TTM period, but profitability metrics such as net profit margin and EBIT margin are negative, indicating operational challenges. The gross profit margin remains strong, suggesting good cost management. However, the negative net income and declining EBIT margins are concerning for long-term profitability.

Balance Sheet

The balance sheet reflects a moderate financial position. The debt-to-equity ratio has improved over time, indicating better leverage management. However, the return on equity is negative in the TTM period, highlighting profitability issues. The equity ratio is stable, suggesting a solid asset base relative to equity.

Cash Flow

Cash flow analysis shows a positive trend in free cash flow growth, indicating improved cash generation capabilities. The operating cash flow to net income ratio is healthy, suggesting efficient cash conversion. However, the free cash flow to net income ratio indicates that cash flow is not fully translating into profitability, which could be a risk factor.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	330.51M	277.25M	232.28M	722.68M	439.44M	46.55M
Gross Profit	194.42M	227.80M	182.12M	460.53M	265.87M	32.64M
EBITDA	-36.86M	45.70M	9.67M	307.70M	95.71M	-46.84M
Net Income	-43.40M	27.31M	-6.39M	293.16M	76.71M	-75.24M
Balance Sheet
Total Assets	946.51M	986.26M	997.10M	985.85M	1.04B	353.27M
Cash, Cash Equivalents and Short-Term Investments	647.82M	713.83M	742.30M	624.39M	545.95M	165.04M
Total Debt	285.02M	254.42M	256.91M	258.01M	257.38M	217.85M
Total Liabilities	412.37M	389.46M	375.02M	404.84M	816.87M	294.58M
Stockholders Equity	534.14M	596.80M	622.07M	581.01M	222.37M	58.69M
Cash Flow
Free Cash Flow	80.54M	60.16M	96.46M	55.58M	326.05M	-103.32M
Operating Cash Flow	90.63M	66.51M	100.56M	62.72M	335.53M	-92.25M
Investing Cash Flow	152.39M	-18.04M	-153.93M	-316.00M	14.22M	-26.53M
Financing Cash Flow	-202.74M	-102.02M	1.39M	19.52M	55.78M	109.50M

Dynavax Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 10.83
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DVAX, the sentiment is Positive. The current price of 10.83 is above the 20-day moving average (MA) of 10.23, above the 50-day MA of 10.02, and below the 200-day MA of 11.11, indicating a neutral trend. The MACD of 0.15 indicates Negative momentum. The RSI at 62.90 is Neutral, neither overbought nor oversold. The STOCH value of 68.91 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DVAX.

Dynavax Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AMPH	74 Outperform	$1.13B	9.00	18.32%	―	1.37%	-18.10%
COLL	70 Outperform	$1.13B	39.25	22.96%	―	26.34%	-32.79%
ANIP	62 Neutral	$1.96B	―	-2.82%	―	38.68%	-160.14%
DVAX	58 Neutral	$1.21B	―	-7.14%	―	26.73%	-310.39%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
PCRX	46 Neutral	$981.78M	―	-15.57%	―	2.25%	-301.59%
EVO	44 Neutral	$1.19B	―	-17.46%	―	-1.19%	5.06%

Dynavax Corporate Events

Dynavax Technologies Advances in Pneumonic Plague Vaccine Study

Dynavax Technologies is conducting a Phase 2 study titled ‘Immunogenicity, Safety, and Tolerability of rF1V-1018 Vaccine in Adults 18 to 55 Years of Age.’ The study aims to evaluate the effectiveness, safety, and tolerability of the rF1V-1018 vaccine, which is significant for preventing pneumonic plague caused by aerosol exposure to Yersinia pestis.

Dynavax Announces Management Restructuring Changes

On October 15, 2025, Dynavax Technologies Corporation’s Board of Directors approved changes in its management structure. David F. Novack will transition from his roles as President and Chief Operating Officer to Senior Vice President and Chief Operating Officer, effective January 1, 2026. Additionally, Robert Janssen, M.D. will be removed from his roles as Chief Medical Officer and Senior Vice President, Clinical Development, Medical and Regulatory Affairs, with his employment concluding by March 2, 2026, as the company searches for a successor.

The most recent analyst rating on (DVAX) stock is a Hold with a $10.00 price target. To see the full list of analyst forecasts on Dynavax stock, see the DVAX Stock Forecast page.

Dynavax Announces Positive Results for Shingles Vaccine

On August 21, 2025, Dynavax announced positive topline results from Part 1 of its Phase 1/2 clinical trial for Z-1018, a novel shingles vaccine candidate. The trial showed that Z-1018 has comparable immune responses to Shingrix, with a favorable tolerability profile, marking a significant step in Dynavax’s efforts to disrupt the shingles vaccine market. Plans are underway to advance Z-1018 into Part 2 of the trial for adults aged 70 and older, aiming to further de-risk the program before Phase 3 development.

The most recent analyst rating on (DVAX) stock is a Hold with a $11.00 price target. To see the full list of analyst forecasts on Dynavax stock, see the DVAX Stock Forecast page.

Dynavax Technologies Reports Strong Q2 Earnings

Dynavax Technologies recently held its earnings call, which conveyed a strong positive sentiment. The company reported significant revenue growth, an increased market share, and successful financial performance. While there were some increases in expenses and a decrease in cash position due to strategic decisions, the overall outlook remains optimistic with updated revenue guidance and progress in clinical pipeline programs.

Dynavax Technologies Reports Strong Q2 2025 Results

Dynavax Technologies Corporation is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative vaccines, primarily within the infectious disease sector, with a unique emphasis on utilizing its CpG 1018® adjuvant to enhance immune responses.